Watch ACET. Know when insiders buy.
One email the day a filing lands. Free.
ACET
Adicet Bio, Inc.
9.59
+0.16 +1.70%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $89.8MP/E —DIV YIELD —FCF YIELD -94.64%REV TTM —NET INCOME −$99MNET CASH —52W 6.11 – 16.64SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$22.3M | −$21.4M | — | -1.99 | −$19.8M | $202K | −$20M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$21.6M | −$20.2M | — | -1.88 | −$21.5M | $37K | −$21.5M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$31.9M | −$30.5M | — | -16.01 | −$20.9M | −$10K | −$20.9M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$28M | −$26.9M | — | -0.29 | −$22.3M | $209K | −$22.5M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$32.4M | −$31.2M | — | -5.48 | −$26.6M | $47K | −$26.7M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$29.9M | −$28.2M | — | -4.96 | −$25.4M | $1.5M | −$26.9M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$30.7M | −$28.7M | — | -20.31 | −$24.1M | $176K | −$24.3M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$33.2M | −$30.5M | — | -0.34 | −$22M | $401K | −$22.4M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$32.8M | −$29.9M | — | -0.33 | −$23.4M | $302K | −$23.7M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$30.9M | −$28M | — | -0.35 | −$22.8M | $239K | −$23.1M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$31.6M | −$29.5M | — | -0.68 | −$23.5M | $136K | −$23.6M | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$52.3M | −$49.9M | — | -1.16 | −$21.2M | $906K | −$22.1M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$122.1M | −$116.8M | — | -16.95 | −$95.2M | $1.7M | −$97M | — | — |
| FY2024 · to Dec 31 | — | — | −$127.6M | −$117.1M | — | -21.33 | −$92.4M | $1.1M | −$93.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$152M | −$142.7M | — | -3.31 | −$93.7M | $4.5M | −$98.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$72.6M | −$69.8M | — | -1.70 | −$44.8M | $16.8M | −$61.5M | — | — |
| FY2021 · to Dec 31 | — | — | −$61.4M | −$62M | — | -2.00 | −$51.1M | $13M | −$64.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$39.2M | −$36.7M | — | -5.01 | −$41.6M | $990K | −$42.5M | — | — |
Every number comes from Adicet Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.